![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
20
Polypeptide Laboratories (sweden) Ab Limhamn Se, based in Switzerland, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Terlipressin, supported by a 'Valid' Certificate of Suitability (CEP) with the number R0-CEP 2019-316 - Rev 00
This Chemical Type CEP, issued on May 21, 2021, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2646 associated with this CEP further emphasizes